Shingles Clinical Trial
Official title:
Systems Biology of Zoster Vaccine Recombinant, Adjuvanted (SHINGRIX)
Verified date | June 2024 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.
Status | Completed |
Enrollment | 38 |
Est. completion date | October 30, 2023 |
Est. primary completion date | April 3, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years and older |
Eligibility | Inclusion Criteria: 1. Subject must be able to understand and provide informed consent. 2. Adults aged 50-60 years, or community dwelling adults aged 70 years and above. Exclusion Criteria: 1. Inability or unwillingness of a subject to give written informed consent or comply with study protocol. 2. Receipt of immune products: - Receipt of blood products within 6 months prior of the first dose of the study Zoster vaccine or expected receipt through 6 months after vaccination with the second dose of the study Zoster vaccine. - Receipt of any vaccine within 4 weeks prior to vaccination with any of the two doses of the study Zoster vaccine or expected receipt within 4 weeks after vaccination with any of the two doses of the study Zoster vaccine. - Receipt of any Zoster or varicella vaccines at any time prior to study entry. 3. Subject taking any non-topical antiviral therapy with activity against herpes viruses, including but not limited to acyclovir, famciclovir, valacyclovir, and ganciclovir 3 days prior to each vaccination or 14 days after. 4. Prior history of shingles. 5. Presence of certain co morbidities or immunosuppressive states such as: - Chronic medical problems including (but not limited to) insulin-dependent diabetes, severe (at the discretion of the investigator or study physician) heart, lung, liver, or kidney diseases; auto immune diseases; severe gastrointestinal diseases; and uncontrolled hypertension. - Impaired immune function or chronic infections including (but not limited to) HIV, hepatitis B or C, tuberculosis, organ transplant, cancer, current and or expected receipt of chemotherapy, radiation therapy, steroids [i.e., > 20 mg of prednisone given daily or on alternative days for 2 weeks or more in the past 90 days); (nasal (less than 1mg/day of fluticasone equivalent inhaled corticosteroid is allowable) and topical steroids are allowed)], antitumor necrosis factor agents, or any other immunosuppressive therapy, anatomic or functional asplenia, congenital immunodeficiency. 6. Conditions that could affect the safety of the subjects such as: - Severe reactions to prior vaccinations. - History of anaphylactic/anaphylactoid reaction to any component of the vaccines. - History of bleeding disorders. 7. Any acute illness, including any fever (> 100.4 F [> 38.0 C], regardless of the route) within 3 days prior to study entry. 8. Social, occupational, or any other condition that in the opinion of the investigator might interfere with compliance with the study and vaccine evaluation. 9. Alcohol or drug abuse and psychiatric conditions that in the opinion of the investigator would preclude compliance with the trial or interpretation of safety or endpoint data. 10. Use of investigational drugs within 12 months of participation. 11. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator or study physician, may pose additional risks from participation in the study, may interfere with the subject's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study. 12. Women of childbearing potential. |
Country | Name | City | State |
---|---|---|---|
United States | The Hope Clinic | Decatur | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University | National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in innate immune signatures | Will be assessed between D0, D1, and D7 and each dose of Zoster vaccine recombinant, adjuvanted, in both age cohorts: 50-60 years and >70 years of age | Baseline, Days 1, 7, 60, 61, 67 | |
Secondary | Change in safety of Zoster vaccine recombinant, adjuvanted | Differences in related adverse events and serious adverse events between each dose of Zoster vaccine recombinant, adjuvanted, in both age cohorts. | Day 270 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01132716 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
|
N/A | |
Completed |
NCT01132729 -
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
|
N/A | |
Completed |
NCT04099706 -
Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT
|
N/A | |
Completed |
NCT04540081 -
Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer
|
N/A | |
Completed |
NCT01527370 -
Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025)
|
Phase 3 | |
Completed |
NCT00534248 -
Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)
|
Phase 3 | |
Completed |
NCT01262300 -
Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents
|
Phase 1 | |
Completed |
NCT00576108 -
A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN)
|
Phase 2 | |
Completed |
NCT00109122 -
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
|
Phase 2 | |
Active, not recruiting |
NCT05871541 -
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
|
Phase 1 | |
Completed |
NCT02114333 -
Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
|
Phase 1 | |
Completed |
NCT00900783 -
A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
|
Phase 2 | |
Completed |
NCT01600079 -
ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024)
|
||
Active, not recruiting |
NCT02444936 -
ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors
|
Phase 4 | |
Recruiting |
NCT05554068 -
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Recruiting |
NCT06238726 -
Nudging Patients to Increase Shingles Vaccination
|
N/A | |
Completed |
NCT02704572 -
Optimal Timing of Zoster Vaccine After Zoster Illness
|
N/A | |
Completed |
NCT00300222 -
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
|
Phase 3 | |
Terminated |
NCT02412917 -
A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia
|
Phase 3 | |
Completed |
NCT00115310 -
Study of NGX-4010 for the Treatment of Postherpetic Neuralgia
|
Phase 3 |